Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04614636
Title FT538 in Subjects With Advanced Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fate Therapeutics
Indications

multiple myeloma

acute myeloid leukemia

Therapies

Cyclophosphamide + Fludarabine

Daratumumab + FT538

Elotuzumab + FT538

FT538

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.